Drug Trial Radar · NCT07875413
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
May 2027
Primary completion
Jun 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- AbelZeta Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.
Conditions
- Large B Cell Lymphoma
- LBCL
- Diffuse Large B Cell Lymphoma (DLBCL)
- Relapse Diffuse Large B Cell Lymphoma
- High Grade B Cell Lymphoma
- FL
- HGBL
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal B Cell Lymphoma
- PMBCL
- HGBL With MYC and BCL2 and/or BCL6 Rearrangements
Interventions
Prizloncabtagene AutoleucelBiological
An Autologous anti-CD19/CD20 chimeric antigen receptor T-cell therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Through Month 24
- Incidence and severity of adverse events (AEs)Time frame: Through Month 24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.